HCMA is a brand dedicated to providing effective solutions for obstructive hypertrophic cardiomyopathy (HCM) and related heart conditions. Their flagship product, Mavacamten, is the first medication designed specifically to treat HCM. Unlike traditional treatments that focus on managing symptoms, Mavacamten targets the underlying biomechanical abnormalities of the condition.

It is an oral, allosteric modulator of cardiac myosin, developed by Myokardia and purchased by Bristol Myers Squibb. In addition to treating HCM, HCMA is also conducting research on the potential of Mavacamten to address other types of heart disease, including non-obstructive HCM and heart failure with preserved ejection fraction. The brand is committed to reducing the need for surgical procedures and is currently testing whether Mavacamten can spare patients from septal reduction therapy.

To ensure safe and effective use of Mavacamten, it is available through a restricted program called the Camzyos REMS Program. This program includes certification for prescribers and pharmacies, as well as ongoing monitoring for patients. HCMA also provides resources and support for patients, including a patient portal, medication guides, and a telephone support line.

They are dedicated to helping individuals with HCM access the care they need for improved quality of life